Abstract. Mammalian stanniocalcin 2 (STC2) is a glycoprotein hormone with multiple functions. The present study determined the importance of STC2 in osteoblast differentiation. It was revealed that the expression of STC2 was increased during the differentiation of MC3T3-E1 cells to osteoblasts and that knockdown of STC2 reduced osteoblast differentiation and mineralization, whereas STC2 overexpression increased differentiation and mineralization. Knockdown of STC2 downregulated the expression of osteoblast-associated genes, including runt-related transcription factor 2, collagen type I α 1 chain, osterix and osteocalcin. Overexpression of STC2 upregulated the expression of these osteoblastic genes. In addition, overexpression of STC2 enhanced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), whereas inhibition of ERK phosphorylation reduced osteoblast differentiation of MC3T3-E1 cells overexpressing STC2. These findings indicated that STC2 may promote osteoblast differentiation and mineralization by regulating ERK activation.
Introduction
Mammalian stanniocalcin 2 (STC2) is a type of glycoprotein hormone, which regulates calcium/phosphate levels (1, 2) . STC2 has been primarily investigated in cancer and has been identified to promote tumor growth and/or invasion in gastric cancer, neuroblastoma and laryngeal squamous cell cancer (3) (4) (5) (6) (7) (8) (9) . Conversely, STC2 has been identified to reduce the migration and invasion of breast tumor cells (10) . STC2 may also affect postnatal growth and animal size (11) (12) (13) . Notably, STC2 may be stimulated by retinoic acid and vitamin D3 (14, 15) , two important triggers for osteoblast differentiation, indicating a possible function of STC2 in osteogenesis.
Extracellular signal-regulated kinase 1/2 (ERK1/2) is important for numerous cellular responses, including cell proliferation, differentiation and survival. ERK may be activated by growth factors to regulate osteoblast differentiation via collagen and α2β1 integrin-mediated signaling (16, 17) . A previous study determined that the introduction of a mutated ERK1 in human osteoblast cells decreased alkaline phosphatase (ALP) activity and deposition of bone matrix proteins, resulting in reduced osteoblast differentiation and matrix mineralization (18) . U0126, a specific inhibitor of mitogen-activated protein kinase (MAPK)/ERK, has been determined to block ascorbic acid (AA)-or bone morphogenetic protein 7/AA-dependent osteoblast-specific gene expression (19) . Previous studies have demonstrated that ERK may regulate osteoblast differentiation via various molecules, including Schnurri-3, secreted phosphoprotein 24, ETS2 repressor factor, twist family bHLH transcription factor 1 and vasopressin (20) (21) (22) (23) (24) . As STC2 was reported to regulate the expression of cyclin D1 and activate ERK1/2 in a dominant-positive manner (25) the present study investigated whether STC2 contributed to osteoblast differentiation in association with the MAPK/ERK signaling pathway.
Materials and methods
Cell culture and transfection. C2C12 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich; Merck Millipore), 100 U/ml penicillin and 100 mg/ml streptomycin. MC3T3-E1 cells were cultured in α-minimum essential medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. C2C12 is a mouse myoblast cell line capable of osteoblastic differentiation, which has been identified as a type of mesenchymal stem cell (26, 27) . MC3T3-E1 is an osteoblast precursor cell line. In order to induce osteoblast differentiation, medium was added with 50 mg/ml ascorbic acid, 10 mM sodium β-glycerophosphate, 1 µM dexamethasone and 50 ng/ml bone morphogenetic protein 2 (all obtained from Sigma-Aldrich; Merck Millipore). To block the activation of the ERK1/2 signaling pathway, 20 µM U0126 (Sigma-Aldrich; Merck Millipore) was added to the medium. STC2 cDNA was cloned into a plenti6 vector (Invitrogen; Thermo Fisher Scientific, Inc.). STC2 short hairpin RNA (shRNA) plasmid was purchased from GeneChem Co., Ltd. (Shanghai, China). Cells were transfected using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol for 6 h at 37˚C.
ALP activity and mineralization analysis. Cells were plated in 96 or 24-well plates at a density of 0.5x10 4 cells/well and cultured in differentiation medium for 0, 3 or 6 days. The medium was changed every 3 days. ALP activity and staining was completed with 1-Step NBT/BCIP substrate solution (Thermo Fisher Scientific, Inc.) as previously described (28) . For mineralization detection, cells were fixed in 70% ethanol for 10 min after 7-14 days induction to differentiation, then stained with Alizarin red solution (2%, pH 4.2) for 15 min at room temperature, then washed with deionized water for removal of nonspecific staining.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total mRNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). cDNA was prepared using PrimeScript RT-PCR kit (Takara Bio, Inc., Otsu, Japan) and was subsequently used for the RT-qPCR analysis performed using FastStart Universal SYBRGreen Master (Roche Diagnostics GmbH, Mannheim, Germany). Primers used were as described by Wang et al (29) . The thermocycling conditions were as follows: First cycle for 10 min at 95˚C, followed by and 40 cycles for 15 sec at 95˚C and 1 min at 60˚C. The primer sequences were as follows: Forward 5'-CAA TAA GGT AGT GAA CAGAC-3', and reverse, 5'-CTT CAA GCC ATA CTG GTCT-3' for osteocalcin (OCN); forward, 5'-CCT GGT AAA GAT GGT GCC-3' and reverse, 5'-CAC CAG GTT CAC CTT TCG CACC-3' for collagen type I α 1 chain (Col1α1); forward, 5'-GAA TGC ACT ACC CAG CCAC-3' and reverse, 5'-TGG CAG GTA CGT GTG GTAG-3' for runt-related transcription factor 2 (Runx2); forward, 5'-GTC AAG AGT CTT AGC CAA ACTC-3' and reverse, 5'-AAA TGA TGT GAG GCC AGA TGG-3' for osterix (OSX); and forward, 5'-CAT GGC CTT CCG TGT TCCTA-3' and reverse, 5'-CCT GCT TCA CCA CCT TCT TGAT-3' for GAPDH. Results were quantified using the 2 -∆∆Cq method (30 
Results
Knockdown of STC2 reduces osteoblast differentiation and mineralization. STC2 was expressed in the C2C12 and MC3T3-E1 cell lines (Fig. 1A) and STC2 protein expression levels were increased during differentiation of MC3T3-E1 cells to osteoblasts (Fig. 1B) .
To investigate the function of STC2 in osteoblast differentiation, STC2 expression was silenced with a specific shRNA in MC3T3-E1 cells (Fig. 1C) . ALP activity is an early marker for osteoblast differentiation; therefore, it was used in the present study to determine whether cells were differentiating. It was revealed that the ALP activity was significantly lower in the shSTC2 group of MC3T3-E1 cells compared with the scramble group (P<0.05; Fig. 1D and E) . Following the induction of osteoblast differentiation, the mineralized nodules detected by Alizarin red staining on day 14 were markedly reduced in the shSTC2 group of MC3T3-E1 cells when compared with the control cells (Fig. 1F) .
Knockdown of STC2 decreases expression levels of osteoblast-specific genes.
The mRNA expression levels of various osteoblast-associated genes were quantified in order to determine the molecular mechanisms underlying the effect STC2 may have on osteoblast differentiation. It was determined that mRNA expression levels of Runx2 ( Fig. 2A) , Col1α1 (Fig. 2B), OSX (Fig. 2C) and OCN (Fig. 2D) were significantly reduced in the shSTC2 group of the MC3T3-E1 cells compared with the scramble group at 3 and 6 days of induction (P<0.01).
Overexpression of STC2 facilitates osteoblast differentiation and mineralization.
To confirm the function of STC2 in osteoblast differentiation, STC2 cDNA was transfected into MC3T3-E1 cells (Fig. 3A) and the cells were treated with differentiation medium. The ALP activity was significantly higher in the STC2 overexpressing cells compared with the control cells (P<0.05; Fig. 3B and C) and an increased number of mineralized nodules were observed in the STC2 overexpressing cells compared with the control cells on day 12 following the induction (Fig. 3D) . The mRNA expression levels of osteoblast-specific genes, including Runx2 (Fig. 4A) , Col1α1 (Fig. 4B) , OSX (Fig. 4C), and OCN (Fig. 4D) were significantly increased at 3 and 6 days of induction, with the exception of OCN at 3 days as no significant difference between the expression levels of the different groups was identified.
STC2 regulates ERK phosphorylation.
To determine how STC2 promoted the differentiation of MC3T3-E1 cells, the present study investigated the MAPK/ERK signaling pathway using western blotting. It was determined that the protein expression level of p-ERK was reduced in the shSTC2 group cells (Fig. 5A) . However, in the MC2T3-E1 cell line transfected with a STC2 overexpressing plasmid, p-ERK expression was increased compared with the control cells (Fig. 5B) . These findings suggest that the regulation of ERK phosphorylation by STC2 may be essential to osteoblast differentiation.
Inhibition of ERK phosphorylation reduces osteoblast-specific gene expression stimulated by STC2 overexpression.
In order to validate the aforementioned findings, the cells were treated with U0126, an effective and selective inhibitor of MAPK kinase (a kinase upstream of ERK1/2) to block the activation of the ERK1/2 signaling pathway and the expression levels of osteoblast-specific genes were determined (Fig. 6) . (Fig. 6A) , OSX (Fig. 6C), and OCN (Fig. 6D) in the 3 and 6 day groups compared with the controls. However, this was not observed for Col1α1 expression in cells that were stimulated by overexpression of STC2 at 6 days. 
Discussion
STC2 has been identified to regulate calcium/phosphate levels and was expressed in limb buds (31) . The present study determined STC2 was expressed in osteoblast precursor cell lines. Thus, the mechanism underlying the effect of STC2 on osteoblast differentiation was investigated using overexpression or knockdown methods. It was determined that overexpression of STC2 promoted ALP activity, mineralization and increased the expression levels of osteoblast-associated genes, including Runx2, Col1α1, OSX, and OCN. Conversely, knockdown of STC2 reduced ALP activity, mineralization and expression levels of osteoblast-associated gene expression. These findings suggest that STC2 may regulate osteoblast differentiation.
Activation of the ERK1/2 pathway is essential for osteoblast differentiation and STC2 has been identified to stimulate the activation of ERK1/2 in a dominant-positive manner (25) ; therefore, STC2 may be important for osteoblast differentiation via regulation of the ERK signaling pathway. It was determined the expression level of p-ERK was higher in MC3T3-E1 cells transfected with a plasmid overexpressing STC2 cells, however, this was reduced in the cells where STC2 was knocked-down compared with the control cells, indicating a possible regulation of STC2 on ERK activation during the differentiation of MC3T3-E1 cells.
In addition, it was revealed that treatment of MC3T3-E1 cells with the ERK inhibitor, U0126, reduced the upregulation of osteoblast-specific genes stimulated by the overexpression of STC2, which was consistent with other results indicating ERK activation was required for STC2 to be able to regulate osteogenic differentiation. To the best of our knowledge, this is the first study to determine that STC2 promoted osteoblast differentiation via regulation of ERK phosphorylation.
In conclusion, the present study identified that STC2 regulated osteoblast differentiation and subsequent matrix mineralization via an ERK-mediated signaling pathway. This suggests STC2 may be a promising target in bone development-associated diseases.
